Funds

Rydex Biotechnology Fund Class H

RYOAX

Rydex Biotechnology Fund Class H

Actions
  • Price (USD)61.92
  • Today's Change0.90 / 1.47%
  • 1 Year change+11.73%
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼
Find Funds and ETFs
Find Funds and ETFs
Use our fund screener to discover other asset types.
 
Funds ScreenerGo to the Funds Screener

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Mid
Investment Style: Blend
Morningstar categoryHealth
Launch date01 Apr 1998
Price currencyUSD
DomicileUnited States
SymbolRYOAX
Manager & start date
Michael Byrum
01 Apr 1998
Adrian Bachman
08 Jul 2022
Brendan Cain
08 Jul 2022
Spencer Crane
08 Jul 2022
Scott Miller
08 Jul 2022
Pricing frequencyDaily
Total net assets
113.18m USD
As of Feb 29 2024
Share class size
5.29m USD
As of Feb 29 2024
Net expense ratio1.64%
Front end load--
Deferred load--
Maximum Redemption Fee--
Min. initial investment2,500.00
USD
Min. additional investment--
Initial IRA1,000.00
USD
Additional IRA--
Available for saleUnited States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
38.70%27.95%0.00%27.95%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
AbbVie Inc
ABBV:NYQ
+14.78%8.54%
Amgen Inc
AMGN:NSQ
+19.42%6.64%
Regeneron Pharmaceuticals Inc
REGN:NSQ
+16.75%4.41%
Vertex Pharmaceuticals Inc
VRTX:NSQ
+33.66%4.36%
Gilead Sciences Inc
GILD:NSQ
-8.86%4.00%
Per cent of portfolio in top 5 holdings: 27.95%
Top 10 Holdings

Diversification

Asset type

Asset type

US stock93.29%
Non-US stock6.40%
Cash2.23%
US bond0.00%
Non-US bond0.00%
Other-1.91%

Top 5 sectors

Equity
Fixed income
Healthcare96.98%
Basic Materials2.71%

Top 5 regions

United States93.29%
United Kingdom3.69%
Eurozone1.62%
Europe - ex Euro1.08%
Sector and region weightings are calculated using only long position holdings of the portfolio.
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2024
All Rights reserved
© 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.